Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Therapies02:49

Cancer Therapies

7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

12.7K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
12.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Novel Cu(II)-complex loaded Eudragit® nanoparticles: design, synthesis, characterization, and enhanced antitumor activity against triple-negative breast cancer.

International journal of pharmaceutics·2026
Same author

In Vitro and In Vivo Effects of a Copper(II)-Hydrazone Complex Against Human Osteosarcoma.

Pharmaceutics·2026
Same author

Synthesis, crystal structure, spectroscopic characterization, theoretical studies and cytotoxicity assays of novel two acylhydrazones and its Cu(II) complexes.

Journal of inorganic biochemistry·2026
Same author

Exploring the Anticancer Properties and Mode of Action of Copper(II)-Furan Acylhydrazone on Human Triple Negative Breast Cancer Cells.

ChemMedChem·2026
Same author

Structural influences on the oxidation and anticancer activities of dicopper(II) complexes containing different selenium and sulfur ligands.

Dalton transactions (Cambridge, England : 2003)·2025
Same author

Advances in copper complexes in cancer treatment.

Drug discovery today·2025

相关实验视频

Updated: Jun 20, 2025

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

57.6K

金属化合物作为抗癌剂对抗骨质肉瘤.

Lucía Santa Maria de la Parra1, Lucía M Balsa1, Ignacio E León2

  • 1CEQUINOR (UNLP, CCT-CONICET La Plata, asociado a CIC), Departamento de Química, Facultad de Ciencias Exactas, Universidad Nacional de La Plata, Blvd. 120 N° 1465, La Plata 1900, Argentina.

Drug discovery today
|July 17, 2024
PubMed
概括

基于金属的化合物显示出治疗骨癌 (骨髓瘤) 的前景. 本综述探讨了它们的化学成分,抗瘤特性和在临床前和临床模型中的作用机制.

关键词:
金属化合物 金属化合物骨癌 骨癌 是一种骨癌.它们的作用机制.骨质肉瘤是骨质肉瘤的一种疾病.

更多相关视频

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.8K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.2K

相关实验视频

Last Updated: Jun 20, 2025

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
11:14

Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay

Published on: November 10, 2013

57.6K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.8K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.2K

科学领域:

  • 药用化学 医学化学
  • 在瘤学瘤学.
  • 材料科学 材料科学 材料科学

背景情况:

  • 骨髓瘤 (OS) 是一种侵袭性骨癌,影响年轻人,转移率和死亡率高.
  • 目前对OS的治疗有局限性,需要开发新的治疗策略.

研究的目的:

  • 审查用于骨髓瘤治疗的金属基化合物的化学和抗瘤特性.
  • 分析这些化合物的结构-活性关系和分子标.
  • 阐明它们的抗癌作用背后的作用机制.

主要方法:

  • 在OS模型中对金属化合物的临床前 (体外,体内) 和临床研究的文献综述.
  • 分析化学结构及其与生物活动的相关性.
  • 对分子点和作用机制的研究.

主要成果:

  • 基于金属的化合物表现出显著的临床前和临床抗瘤活性对骨髓瘤.
  • 金属化合物的特定结构特征与其有效性有关.
  • 它们的作用机制涉及各种分子点和途径.

结论:

  • 金属化合物代表了骨髓瘤治疗的有希望的药物类别.
  • 对结构-活动关系和机制的进一步研究可以优化其临床应用.
  • 针对性地开发金属制药可以改善骨髓瘤患者的治疗结果.